{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:39:20Z","timestamp":1767983960100,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s10388-023-00987-0","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:35:30Z","timestamp":1675841730000},"page":"533-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"20","author":[{"given":"Takumi","family":"Habu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Kumanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatsugu","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Mitsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"987_CR1","unstructured":"Cancer mortality from Vital Statistics in Japan (1958-2020). Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare). 2023. https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html."},{"issue":"1","key":"987_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10388-016-0556-2","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th edition: part II and III. Esophagus. 2017;14(1):37\u201365.","journal-title":"Esophagus"},{"issue":"1","key":"987_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-021-00879-1","volume":"19","author":"M Watanabe","year":"2022","unstructured":"Watanabe M, Toh Y, Ishihara R, et al. Comprehensive registry of esophageal cancer in Japan, 2014. Esophagus. 2022;19(1):1\u201326.","journal-title":"Esophagus"},{"issue":"10","key":"987_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jjco\/hyh107","volume":"34","author":"K Ishida","year":"2004","unstructured":"Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)\/ Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol. 2004;34(10):615\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"987_CR5","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1200\/JCO.1999.17.9.2915","volume":"17","author":"A Ohtsu","year":"1999","unstructured":"Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and\/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17(9):2915\u201321.","journal-title":"J Clin Oncol"},{"issue":"4","key":"987_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/cas.12622","volume":"106","author":"M Shinoda","year":"2015","unstructured":"Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407\u201312.","journal-title":"Cancer Sci"},{"issue":"6","key":"987_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jjco\/hyi095","volume":"35","author":"M Tahara","year":"2005","unstructured":"Tahara M, Ohtsu A, Hironaka S, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005;35(6):316\u201323.","journal-title":"Jpn J Clin Oncol"},{"key":"987_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06716-5","author":"H Bando","year":"2020","unstructured":"Bando H, Kotani D, Tsushima T, et al. TENERGY: multicenter phase II study of atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. BMC Cancer. 2020. https:\/\/doi.org\/10.1186\/s12885-020-06716-5.","journal-title":"BMC Cancer"},{"issue":"11","key":"987_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/jjco\/hyz112","volume":"49","author":"M Terada","year":"2019","unstructured":"Terada M, Hara H, Daiko H, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: Triangle). Jpn J Clin Oncol. 2019;49(11):1055\u201360.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"987_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"987_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ijc.2910530208","volume":"53","author":"H Kato","year":"1993","unstructured":"Kato H, Tachimori Y, Watanabe H, Iizuka T. Evaluation of the new (1987) TNM classification for thoracic esophageal tumors. Int J Cancer. 1993;53(2):220\u20133.","journal-title":"Int J Cancer"},{"issue":"6","key":"987_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.21037\/jtd.2016.04.08","volume":"8","author":"Y Chen","year":"2016","unstructured":"Chen Y, Zhang Z, Jiang G, Zhao K. Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy. J Thorac Dis. 2016;8(6):1155\u201361.","journal-title":"J Thorac Dis"},{"issue":"11","key":"987_CR13","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/bjc.2016.350","volume":"115","author":"T Yokota","year":"2016","unstructured":"Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328\u201334.","journal-title":"Br J Cancer"},{"issue":"5","key":"987_CR14","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.ijrobp.2007.08.060","volume":"70","author":"R Koike","year":"2008","unstructured":"Koike R, Nishimura Y, Nakamatsu K, Kanamori S, Shibata T. Concurrent chemoradiotherapy for esophageal cancer with malignant fistula. Int J Radiat Oncol Biol Phys. 2008;70(5):1418\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"987_CR15","first-page":"5039","volume":"37","author":"A Kumabe","year":"2017","unstructured":"Kumabe A, Zenda S, Motegi A, Onozawa M. Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma. Anticancer Res. 2017;37(9):5039\u201344.","journal-title":"Anticancer Res"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-023-00987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-023-00987-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-023-00987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:10:48Z","timestamp":1685625048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-023-00987-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["987"],"URL":"https:\/\/doi.org\/10.1007\/s10388-023-00987-0","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"assertion":[{"value":"8 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed according to the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The study protocol was approved by the institutional review boards of the National Cancer Center (2021-222) and the Aichi Cancer Center (2021-0-086).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}},{"value":"Saori Mishima received honoraria from Merck Serono biopharma, and received research funding from Roche Diagnostics. Daisuke Kotani received honoraria from Takeda, Chugai Pharmaceutical, Lilly, MSD, Ono, Taiho Pharmaceutical, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, and Merck Sereno biopharma, and received research funding from Ono Pharmaceutical, MSD, Novartis, Servier, Janssen, IQVIA, Syneos health, and Cmic Shiftzero. Shigenori Kadowaki received honoraria from Eli Lilly, Taiho Pharmaceutical, Ono Pharmaceutical, BMS, Chugai Pharmaceutical,Bayer, Merck Serono, Daiichi Sankyo and Eisai, and received research funding from Taiho Pharmaceutical, Eli Lilly, MSD, Chugai Pharmaceutical, Nobelpharma, Ono Pharmaceutical, Daiichi Sankyo and Yansen. Shohei Koyama received honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Chugai Pharmaceutical, and MSD, and received research funding outside the scope of this work from Bristol-Myers Squibb, Ono Pharmaceutical and Otsuka Pharmaceutical. Hiroyoshi Nishikawa received research funding and honoraria from Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb and MSD, and research funding from Taiho Pharmaceutical, Daiichi-Sankyo, Kyowa Kirin, Zenyaku Kogyo, Oncolys BioPharma, Debio pharma, Asahi-Kasei, Sysmex, Fujifilm, Rakuten Medical, SRL, Astellas Pharmaceutical, Sumitomo Dainippon Pharma and BD Japan outside of this study. Kei Muro received honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, Bristol-Myers Squibb, Eli Lilly and Daiichi Sankyo, and received research funding from Taiho, Eisai, Astellas, Amgen, Ono Pharmaceutical, MSD, Novartis, Chugai Pharmaceutical, Sanofi. He also received consulting fees from Astra Zeneca, Ono Pharmaceutical and Amgen. Takashi Kojima received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Covidien Japan, MSD, Taiho Pharmaceutical, Oncolys BioPharma, and received research funding from Ono Pharmaceutical, Bristol-Myers Squibb, BeiGene, EPS, MSD, Amgen, Shionogi, Chugai Pharmaceutical, Taiho Pharmaceutical, Parexel international and Merck Biopharma. Hideaki Bando received research funding from Ono Pharmaceutical and honoraria from Taiho Pharmaceutical and Eli Lilly Japan. Hiroyuki Nishikawa is an editorial board member. Takumi Habu, Ryosuke Kumanishi, Takatsugu Ogata, Takeshi Fujisawa, Masaki Nakamura, Hidehiro Hojo, Hisashi Fujiwara, Shogo Kumagai, Takeo Fujita, Takahiro Kinoshita, Tomonori Yano, Masahiro Tajika and Shuichi Mitsunaga declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights statement and informed consent"}}]}}